Engineers Gate Manager’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-56,498
| Closed | -$1.46M | – | 2466 |
|
|
2025
Q4 | $1.46M | Buy |
56,498
+8,688
| +18% | +$207K | 0.02% | 854 |
|
|
2025
Q3 | $1.23M | Sell |
47,810
-32,151
| -40% | -$790K | 0.01% | 1042 |
|
|
2025
Q2 | $1.91M | Buy |
79,961
+35,780
| +81% | +$902K | 0.02% | 753 |
|
|
2025
Q1 | $1.1M | Sell |
44,181
-45,168
| -51% | -$1.08M | 0.02% | 1015 |
|
|
2024
Q4 | $1.68M | Buy |
89,349
+75,804
| +560% | +$1.33M | 0.03% | 709 |
|
|
2024
Q3 | $204K | Buy |
13,545
+1,472
| +12% | +$25.2K | ﹤0.01% | 1798 |
|
|
2024
Q2 | $345K | Sell |
12,073
-7,316
| -38% | -$208K | 0.01% | 1387 |
|
|
2024
Q1 | $567K | Buy |
+19,389
| New | +$596K | 0.01% | 1133 |
|
|
2023
Q4 | – | Sell |
-9,294
| Closed | -$285K | – | 2176 |
|
|
2023
Q3 | $285K | Buy |
+9,294
| New | +$335K | 0.01% | 1345 |
|
|
2023
Q2 | – | Sell |
-16,693
| Closed | -$681K | – | 1949 |
|
|
2023
Q1 | $681K | Sell |
16,693
-35,406
| -68% | -$1.41M | 0.03% | 822 |
|
|
2022
Q4 | $2.01M | Buy |
+52,099
| New | +$2.53M | 0.12% | 189 |
|
|
2021
Q3 | – | Sell |
-17,010
| Closed | -$1.03M | – | 1891 |
|
|
2021
Q2 | $1.03M | Buy |
17,010
+750
| +5% | +$47.5K | 0.07% | 423 |
|
|
2021
Q1 | $1.14M | Buy |
16,260
+11,819
| +266% | +$844K | 0.06% | 527 |
|
|
2020
Q4 | $266K | Buy |
4,441
+180
| +4% | +$10.5K | 0.01% | 1370 |
|
|
2020
Q3 | $256K | Buy |
+4,261
| New | +$248K | 0.01% | 1325 |
|
|
2020
Q2 | – | Sell |
-45,266
| Closed | -$1.52M | – | 1915 |
|
|
2020
Q1 | $1.52M | Sell |
45,266
-21,699
| -32% | -$901K | 0.11% | 262 |
|
|
2019
Q4 | $3.03M | Buy |
+66,965
| New | +$2.84M | 0.13% | 217 |
|
|
2019
Q3 | – | Sell |
-76,881
| Closed | -$3.34M | – | 1550 |
|
|
2019
Q2 | $3.34M | Sell |
76,881
-10,248
| -12% | -$435K | 0.18% | 158 |
|
|
2019
Q1 | $3.32M | Buy |
87,129
+24,711
| +40% | +$964K | 0.2% | 150 |
|
|
2018
Q4 | $2.69M | Sell |
62,418
-9,335
| -13% | -$436K | 0.21% | 137 |
|
|
2018
Q3 | $3.53M | Buy |
71,753
+10,734
| +18% | +$464K | 0.27% | 101 |
|
|
2018
Q2 | $1.96M | Buy |
+61,019
| New | +$2.11M | 0.15% | 215 |
|
|
2017
Q2 | – | Sell |
-12,496
| Closed | -$570K | – | 760 |
|
|
2017
Q1 | $570K | Buy |
+12,496
| New | +$540K | 0.06% | 425 |
|
|
2016
Q1 | – | Sell |
-13,094
| Closed | -$1M | – | 790 |
|
|
2015
Q4 | $1M | Buy |
+13,094
| New | +$741K | 0.07% | 400 |
|
Other funds holding PCRX
DPCM
Engineers Gate Manager's PCRX Position: Q1 2026 in Review
Engineers Gate Manager sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 56,498 shares — an estimated $1.46M sold.
Engineers Gate Manager first reported a position in PCRX in Q4 2015 and held it in 24 quarters. The position peaked at $3.53M in Q3 2018. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Engineers Gate Manager reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
- Engineers Gate Manager sold 56,498 Pacira BioSciences shares in Q1 2026, an estimated $1.46M.
- Engineers Gate Manager first reported a position in Pacira BioSciences in Q4 2015 and held it in 24 quarters.
- Engineers Gate Manager's Pacira BioSciences position peaked at $3.53M in Q3 2018.
- 242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.